- 光算穀歌外鏈
上年同期淨虧損為2.25億元
时间：2010-12-5 17:23:32 作者：光算穀歌廣告 来源：光算穀歌外鏈 查看： 评论：0内容摘要：上年同期淨虧損為2.25億元；攤薄後每股ADS收益為0.166元，（文章來源：界麵新聞）上年同期每股A光算谷歌外链DS虧損為0.174元。同比增長53%；淨利潤2.16億元，霧芯科光光算谷歌seo算谷上年同期淨虧損為2.25億元；攤薄後每股ADS收益為0.166元，（文章來源：界麵新聞）上年同期每股A
- 最近更新
- 2025-06-17 18:12:03福建省省長趙龍：福建省清潔能源裝機比重已達63%
- 2025-06-17 18:12:03“密衛轉債”轉股價格預計觸發向下修正條件，投資者需注意投資風險
- 2025-06-17 18:12:03全球首張無人駕駛載人航空器生產許可證頒發 或將快速實現規模化量產
- 2025-06-17 18:12:03廣聯達：聘任馮健雄為公司董事會秘書
- 2025-06-17 18:12:03陽普醫療大跌逾14%
- 2025-06-17 18:12:03微芯生物：公司預期在4月到5月小細胞肺癌的III期數據會揭盲
- 2025-06-17 18:12:03交易異動！一鳴食品：近3個交易日上漲21.19% 無未披露的重大信息
- 2025-06-17 18:12:03華林證券補繳近5000萬元稅款 預計影響今年歸母淨利潤
- 热门排行
- 2025-06-17 18:12:03高新發展：4月20日召開終止重大資產重組投資者說明會
- 2025-06-17 18:12:03新天地：2023年淨利同比增長20.16% 擬10轉4股派4元
- 2025-06-17 18:12:03“一覺醒來一個月‘幹飯錢’沒了！”
- 2025-06-17 18:12:03北銀消金新上任一名總經理助理 公司2023年淨利有望破億
- 2025-06-17 18:12:03貴州燃氣：計提減值準備3460.33萬元
- 2025-06-17 18:12:03智能駕駛計算方案提供商地平線向港交所遞交上市申請
- 2025-06-17 18:12:03金海通(603061.SH)：旭諾投資擬減持180萬股，不超過公司總股本的3%
- 2025-06-17 18:12:03靜安區為2023年度經濟貢獻二百強企業頒獎
- 友情链接
- https://synapse.patsnap.com/article/acupuncture-reduces-methadone-dose-opioid-craving
- https://synapse.patsnap.com/blog/shanghai-yingli-pharmaceutical-submits-a-marketing-application-for-pi3kd-inhibitor-linperlisib
- https://synapse.patsnap.com/article/ab-science-announces-2023-revenues-and-activity-update
- https://synapse.patsnap.com/drug/fdcfd58b59be4b059745df49c11d9524
- https://synapse.patsnap.com/drug/1d9adfcf2b8f44ea9a07c1de7392141d
- https://synapse.patsnap.com/drug/e554384c3230456093f99033c02c9967
- https://synapse.patsnap.com/drug/7846578bdf1e4e8898cce07919654120
- https://synapse.patsnap.com/drug/6380d03386b8e014b890a097ebe2dce5
- https://synapse.patsnap.com/drug/8bfa8c2c27a64ad6af4a1140331b7702
- https://synapse.patsnap.com/drug/115fef96985b4685915dd479fea3e293
- https://synapse.patsnap.com/article/what-are-the-side-effects-of-ethanol
- https://synapse.patsnap.com/drug/ad3afd5143aadaaa2493e3fb5b5ee2d3
- https://synapse.patsnap.com/drug/9d058b673e584d03b202598fd03dd795
- https://synapse.patsnap.com/blog/instil-bio-and-immuneonco-partner-for-imm2510-and-imm27m-development
- https://synapse.patsnap.com/drug/632644fcc97c33ccab4822d278101f12
- https://synapse.patsnap.com/article/ionis-unveils-phase-3-trial-design-for-ion582-in-angelman-syndrome
- https://synapse.patsnap.com/drug/c209cb5aa0374f3f972d5652dc426a2a
- https://synapse.patsnap.com/drug/4a1a1ab039504ddfa83f39601e636679
- https://synapse.patsnap.com/drug/6c85ce67cc174159a981f69baff36221
- https://synapse.patsnap.com/article/what-are-interferon-receptor-family-antagonists-and-how-do-they-work
- https://synapse.patsnap.com/drug/e359ed9eef15430b91b30942590f73e1
- https://synapse.patsnap.com/drug/4646f8d82d704261869895c7dca120e0
- https://synapse.patsnap.com/article/what-is-dtcp-used-for
- https://synapse.patsnap.com/drug/bb7e7e9b4e7a45d98eb061eb52f7db48
- https://synapse.patsnap.com/article/medicinova-to-present-mn-001-studies-at-92nd-eas-congress-2024
- https://synapse.patsnap.com/article/asco24-jj-reports-four-deaths-in-early-prostate-cancer-trial
- https://synapse.patsnap.com/article/what-are-proliferation-marker-protein-ki-67-expression-inhibitors-and-how-do-they-work
- https://synapse.patsnap.com/article/what-are-mir-17-inhibitors-and-how-do-they-work
- https://synapse.patsnap.com/article/what-drugs-are-in-development-for-autoimmune-diseases
- https://synapse.patsnap.com/drug/aae803df2e6848adac3acdf3510eeabe